Drugs / VIS513
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06551844 | Apr 2026 → Dec 2029 expected | dengue disease | Oxford University Clinical Research Unit, Vietnam | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIS513 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06551844 ↗ |
| Action | Inhibit | “It has shown potent, specific neutralization of all four serotypes of DENV.” NCT06551844 ↗ |
| Modality | Monoclonal antibody | “VIS513 is an engineered humanised monoclonal antibody” NCT06551844 ↗ |
| Route | Intravenous | “via an intravenous line” NCT06551844 ↗ |